With a surge in new cases surpassing daily highs across the US, it is clear that the battle against COVID-19 will continue for the foreseeable future. While much of the world tries to go back to “normal”, healthcare workers on the frontlines continue to work tirelessly and put themselves at risk every...Read the Full Article
Over the past several weeks, we have seen a number of provinces and states relax restrictions and open up further. Combined with the start of summer, this has caused many to ease on social distancing measures some more so than perhaps expected or hoped for. While we are huge advocates of maintaining...Read the Full Article
As a leader in the Canadian life science investment community, Lumira Ventures has been closely monitoring and engaging with companies who are developing COVID-19 treatments and vaccines. While our portfolio companies and employees within have been significantly impacted by the current crisis, much like the broader innovation and startup ecosystem, we have...Read the Full Article
As a leader in the Canadian life science investment community, Lumira Ventures has been closely monitoring and engaging with companies who are developing COVID-19 treatments and vaccines. While our portfolio companies and employees within have been significantly impacted by the current crisis, much like the broader innovation and startup ecosystem, we have...Read the Full Article
At Lumira Ventures, the past couple of months have been consumed with evaluating new investment opportunities, and working with our portfolio companies, governments, and the venture and healthcare ecosystems to ensure that our companies and all innovation-centric companies broadly are well positioned to weather these challenging times and flourish in a post-COVID-19...Read the Full Article
Earlier this month, 43 of the most promising companies in the Canadian health science industry came together at the OBIO Niagara Investment Summit, where they showcased their innovations to over 40 investors from across North America and Japan to pave the path to the investments needed to fully commercialize products. Innovations featured...Read the Full Article
(Above) Daniel Hétu, Managing Director at Lumira Ventures CQDM, a biopharma-based research consortium created in 2008 with the mission to fund the development of innovative technologies to accelerate drug discovery and development, has appointed Lumira Ventures Managing Director, Daniel Hétu to its Board of Directors, in addition to Sarah Jenna, Co-Founder and...Read the Full Article
Source: MaRS Discovery District Lumira Ventures is proud to sponsor the 6th Annual Health Innovation Week (#HIW2019) from April 1-5, 2019 presented by MaRS Discovery District and Founding Partner, TO Health! Health Innovation Week (#HIW2019) is Canada's largest gathering of health startups, investors and the health ecosystem and allows participants to network,...Read the Full Article
The Consulate General of Canada in Boston and the Trade Commissioner Service has announced highlights of the Canadian Technology Accelerator in Boston. Lumira Ventures’ Boston-based partner Gerry Brunk has served as a team member and lead mentor for the CTA program since its inception. The Canadian Technology Accelerator in Boston (CTA@Boston) is...Read the Full Article
Today, Lumira Ventures is excited to debut its new website at www.lumiraventures.com, new branding and change of name from Lumira Capital to Lumira Ventures. Over the past 30 years, Lumira has been at the forefront of the healthcare investment industry. Driven by their unique strategy, the team has overseen the investment of...Read the Full Article
TORONTO--(BUSINESS WIRE)--Bloom Burton & Co. (“Bloom Burton”) is pleased to announce the three finalists for the 2018 Bloom Burton Award. The finalists are: Clarissa Desjardins, Founder and CEO, Clementia Pharmaceuticals Inc.; Richard Glickman, Founder, CEO and Chairman of the Board, Aurinia Pharmaceuticals Inc.; and Ali Tehrani, Co-founder, President and CEO, Zymeworks Inc....Read the Full Article
The Canadian Venture Capital Association interview between CVCA CEO, Mike Woollatt and Peter van der Velden, Managing General Partner, Lumira Capital. Learn more here.Read the Full Article
The Research Institute of St. Joe’s Hamilton is set to receive philanthropic funding from Lumira Capital to support research initiatives at the hospital. Lumira Capital – a leading North American healthcare venture capital firm – has launched a new philanthropic initiative, the first of its kind in Canada. Up to fifteen healthcare...Read the Full Article
TORONTO (June 8, 2017) – Northleaf Venture Catalyst Fund (NVCF) today announced that it has made a $15 million lead commitment to Lumira Capital IV, a leading late-stage venture capital fund investing in high-potential biopharmaceutical and medical device companies. With the closing of this investment, Northleaf has completed the NVCF investment program,...Read the Full Article
Lumira Partners donate a portion of their profits to support foundations' research, translational medicine and healthcare access missions. Affiliated foundation institutions gain access to Lumira Capital team and extended network to accelerate their innovation strategies. TORONTO, June 6, 2017 /CNW/ - Lumira Capital, a leading North American healthcare venture capital firm, announced today...Read the Full Article
VANCOUVER, April 4, 2017 – Kensington Capital Partners Limited, the Manager of the BC Tech Fund, today announced a new investment by the Fund into Lumira Capital IV, L.P., a new health care and life science venture capital fund managed by Lumira Capital. Dr. Richard Glickman, Chairman and Chief Executive Officer of...Read the Full Article